214 related articles for article (PubMed ID: 34831445)
21. AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer.
Daniel M; Knutson TP; Sperger JM; Li Y; Singh A; Stahlfeld CN; Passow C; Auch B; Lang JM; Dehm SM
Endocr Relat Cancer; 2021 Aug; 28(9):645-655. PubMed ID: 34280123
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.
Kubota Y; Hatakeyama S; Yoneyama T; Yoneyama MS; Hamano I; Konishi S; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
World J Urol; 2021 Sep; 39(9):3265-3271. PubMed ID: 33675416
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of potential regulatory signaling molecules correlate with androgen receptor splice variants AR-V7 and AR-V567es in prostate cancer metastasis.
Kiliccioglu I; Bilen CY; Sozen S; Konac E
Gene; 2021 Mar; 772():145377. PubMed ID: 33359129
[TBL] [Abstract][Full Text] [Related]
24. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW
Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290
[TBL] [Abstract][Full Text] [Related]
25. Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with Prognosis of Prostate Cancer Patients.
Lieb V; Abdulrahman A; Weigelt K; Hauch S; Gombert M; Guzman J; Bellut L; Goebell PJ; Stöhr R; Hartmann A; Wullich B; Taubert H; Wach S
Cells; 2022 Nov; 11(22):. PubMed ID: 36429046
[TBL] [Abstract][Full Text] [Related]
26. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES; Lu C; Wang H; Luber B; Nakazawa M; Roeser JC; Chen Y; Mohammad TA; Chen Y; Fedor HL; Lotan TL; Zheng Q; De Marzo AM; Isaacs JT; Isaacs WB; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
N Engl J Med; 2014 Sep; 371(11):1028-38. PubMed ID: 25184630
[TBL] [Abstract][Full Text] [Related]
27. CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.
Bastos DA; Antonarakis ES
Expert Rev Mol Diagn; 2018 Feb; 18(2):155-163. PubMed ID: 29319382
[TBL] [Abstract][Full Text] [Related]
28. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
[TBL] [Abstract][Full Text] [Related]
29. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
30. [TMPRSS2-Erg/AR-V7: Prognostic value of tests in urine and biopsy rince material in prostate cancer].
Plante G; Bories PN; Denjean L; Pigat N; Sibony M; Goffin V; Barry Delongchamps N
Prog Urol; 2020 Mar; 30(3):162-171. PubMed ID: 32127312
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
Krause WC; Shafi AA; Nakka M; Weigel NL
Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?
Sprenger C; Uo T; Plymate S
Ann Oncol; 2015 Sep; 26(9):1805-1807. PubMed ID: 26199394
[No Abstract] [Full Text] [Related]
33. AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC.
Erb HHH; Sparwasser P; Diehl T; Hemmerlein-Thomas M; Tsaur I; Jüngel E; Sommer U; Baretton GB; Haferkamp A; Neisius A; Thomas C
Urol Int; 2020; 104(3-4):253-262. PubMed ID: 31955172
[TBL] [Abstract][Full Text] [Related]
34. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
35. Multiparametric liquid biopsy analysis in metastatic prostate cancer.
Hodara E; Morrison G; Cunha A; Zainfeld D; Xu T; Xu Y; Dempsey PW; Pagano PC; Bischoff F; Khurana A; Koo S; Ting M; Cotter PD; Moore MW; Gunn S; Usher J; Rabizadeh S; Danenberg P; Danenberg K; Carpten J; Dorff T; Quinn D; Goldkorn A
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30702443
[TBL] [Abstract][Full Text] [Related]
36. Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis.
Morrison G; Buckley J; Ostrow D; Varghese B; Cen SY; Werbin J; Ericson N; Cunha A; Lu YT; George T; Smith J; Quinn D; Duddalwar V; Triche T; Goldkorn A
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269713
[TBL] [Abstract][Full Text] [Related]
37. An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells.
Sieuwerts AM; Mostert B; van der Vlugt-Daane M; Kraan J; Beaufort CM; Van M; Prager WJC; De Laere B; Beije N; Hamberg P; Westgeest HM; Tascilar M; Dirix LY; Onstenk W; de Wit R; Lolkema MP; Mathijssen RHJ; Martens JWM; Sleijfer S
J Mol Diagn; 2018 May; 20(3):316-325. PubMed ID: 29474983
[TBL] [Abstract][Full Text] [Related]
38. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
[TBL] [Abstract][Full Text] [Related]
39. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
[TBL] [Abstract][Full Text] [Related]
40. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]